Drugs Containing Excipient (Inactive Ingredient) BENTONITE

Generic drugs containing BENTONITE excipient

Company	Ingredient	NDC	Excipient
Padagis Israel Pharmaceuticals Ltd	selenium sulfide	45802-040	BENTONITE
A-S Medication Solutions	selenium sulfide	50090-0242	BENTONITE
A-S Medication Solutions	selenium sulfide	50090-2166	BENTONITE

Bentonite Excipient Market Dynamics and Financial Trajectory

Last updated: August 6, 2026

Bentonite is a low-cost, mineral-based pharmaceutical excipient used mainly as a suspending agent, adsorbent, viscosity modifier, stabilizer, and tablet-processing aid. Its commercial outlook is stable rather than high-growth. Volume demand is supported by oral suspensions, topical products, antidiarrheal preparations, veterinary medicines, and nutraceuticals, while revenue growth depends on pharmaceutical-grade purification, testing, packaging, and regulatory compliance.

Bentonite is not a branded drug and does not have an Orange Book patent estate. The principal commercial risks are raw-material variability, heavy-metal contamination, microbiological quality, supply concentration, and substitution by synthetic or more consistent excipients.

What is bentonite used for in pharmaceutical formulations?

Bentonite is a naturally occurring clay composed primarily of montmorillonite, a swelling aluminum phyllosilicate. Pharmaceutical grades are selected for their swelling capacity, adsorption properties, rheology, and ability to form stable dispersions.

Pharmaceutical function	Typical product application	Commercial value
Suspending agent	Oral liquids, antacids, mineral suspensions	Prevents sedimentation
Viscosity modifier	Topical gels, creams, lotions	Controls flow and product texture
Adsorbent	Gastrointestinal products and detoxification formulations	Binds selected substances
Stabilizer	Suspensions and emulsions	Improves physical stability
Tablet-processing aid	Granulation and solid-dose products	Supports flow and binding
Clarifying or filtering aid	Selected liquid products	Removes suspended material
Veterinary excipient	Oral pastes, powders, and suspensions	Supports high-volume animal-health products

Bentonite grades differ materially. Sodium bentonite has high swelling capacity and is often preferred for suspension and rheology applications. Calcium bentonite has lower swelling behavior and is used where different adsorption or processing characteristics are required. Pharmaceutical buyers usually specify mineral identity, particle-size distribution, swelling index, loss on drying, pH, microbial limits, and elemental impurities.

The term “bentonite” does not identify a single chemically uniform substance. The commercial specification is therefore as important as the mineral name.

How large is the pharmaceutical bentonite excipient market?

No widely accepted public dataset reports pharmaceutical bentonite as a standalone global market. Producers generally include it within broader categories such as specialty minerals, functional additives, pharmaceutical excipients, or industrial bentonite. Public revenue disclosures therefore cannot reliably isolate pharmaceutical bentonite sales.

The market is best understood as a niche within three larger segments:

1. Industrial and construction bentonite, which accounts for most global bentonite volume.
2. Food, feed, cosmetics, and personal-care bentonite.
3. Pharmaceutical and high-purity bentonite, which represents a smaller volume but commands higher prices and tighter quality controls.

Pharmaceutical-grade material typically generates a premium over drilling or foundry grades because of additional processing, analytical testing, controlled milling, traceability, and documentation. The premium can be substantial, but it varies by mineral source, purity specification, order size, and packaging format.

Demand is relatively defensive. Bentonite is inexpensive per formulation and usually represents a small portion of a finished product’s cost. A manufacturer is therefore less likely to reformulate solely because of moderate bentonite price movements. Supply interruptions, regulatory findings, or batch variability create greater commercial risk than ordinary price inflation.

What is driving bentonite excipient demand?

Oral suspension and gastrointestinal products

Bentonite remains relevant in oral suspensions where sedimentation control and adsorption are required. Demand is linked to generic medicines, over-the-counter gastrointestinal products, antacids, and traditional mineral-based preparations.

Growth is constrained by the availability of alternatives, including colloidal silicon dioxide, magnesium aluminum silicate, xanthan gum, cellulose derivatives, carbomers, and synthetic polymers. Formulators often select these alternatives when they need tighter rheological control or a more uniform composition.

Topical and dermatological formulations

Bentonite is used in some creams, gels, pastes, and suspensions. Topical demand benefits from continued generic dermatology production and contract manufacturing. The main limitations are color, sensory profile, dispersion behavior, and potential interaction with active ingredients or preservatives.

Veterinary and animal-health products

Veterinary products can provide a meaningful outlet for bentonite, particularly in oral pastes, powders, suspensions, and feed-related formulations. This segment may be less restrictive than human pharmaceuticals in some applications, but major manufacturers still require consistent mineral quality and contaminant controls.

Nutraceutical and natural-product formulations

Consumer demand for mineral-based products supports sales of selected bentonite grades. This channel carries regulatory and reputational risk because claims involving detoxification, internal cleansing, or heavy-metal binding may trigger enforcement scrutiny. Pharmaceutical suppliers generally separate validated excipient grades from consumer products marketed with unapproved health claims.

Which companies supply pharmaceutical-grade bentonite?

The supply chain includes mineral owners, processors, specialty-mineral companies, excipient distributors, and regional pharmaceutical-material suppliers. Major global mineral companies such as Imerys and Ashapura Minechem participate in industrial and specialty-mineral markets, while bentonite specialists and regional processors supply specific grades under proprietary or private-label names. Distributor participation is significant because pharmaceutical customers often purchase in smaller volumes than drilling-fluid or foundry customers.

Supplier type	Role in the market	Competitive advantage
Mineral producer	Owns or controls deposits	Resource security and cost position
Specialty processor	Refines, dries, mills, and standardizes clay	Pharmaceutical-quality consistency
Excipient distributor	Imports, repackages, and manages documentation	Local inventory and regulatory support
Contract manufacturer	Incorporates bentonite into finished products	Formulation and process knowledge
Integrated global minerals group	Supplies multiple industries	Scale, testing infrastructure, and geographic reach

The strongest suppliers are not necessarily the lowest-cost miners. Pharmaceutical customers value validated change control, stable specifications, audit readiness, batch traceability, and the ability to support regulatory filings.

What are the main cost and margin drivers for bentonite excipients?

The cost structure is dominated by mineral extraction and processing, but pharmaceutical-grade economics are affected by several additional factors:

• Deposit quality and montmorillonite content.
• Overburden removal and mine access.
• Drying energy and fuel costs.
• Milling and particle-size control.
• Purification and removal of sand, quartz, and other minerals.
• Testing for lead, arsenic, mercury, cadmium, and other elemental impurities.
• Microbiological testing and controlled packaging.
• Freight, especially for low-value bulk material.
• Quality agreements, audits, and regulatory documentation.
• Inventory requirements for customers with long product lifecycles.

Bentonite prices are usually more sensitive to logistics and energy than to pharmaceutical demand. Bulk shipments can be uneconomic over long distances because the product has a relatively low value-to-weight ratio. Local or regional processing therefore provides a structural advantage.

Margins are generally higher for packaged, tested, and specification-controlled pharmaceutical material than for untreated industrial bentonite. They remain below the margins of complex synthetic excipients or patented delivery technologies because bentonite has limited differentiation at the chemical-composition level.

What is the financial trajectory for pharmaceutical bentonite?

The financial trajectory is likely to be steady, with modest nominal growth and periodic margin volatility. Public company accounts do not normally disclose pharmaceutical bentonite separately, so the segment should be assessed through operating indicators rather than reported standalone revenue.

Financial factor	Expected direction	Effect on suppliers
Pharmaceutical demand	Stable to modest growth	Supports recurring orders
Generic drug production	Positive	Expands excipient consumption
Energy and drying costs	Volatile	Pressures gross margins
Freight costs	Volatile	Favors regional supply
Quality requirements	Rising	Increases testing costs but supports premium pricing
Substitution risk	Persistent	Limits long-term pricing power
Customer concentration	Potentially high	Creates contract-renewal risk
Mining and environmental regulation	Tightening	Raises compliance and closure costs

Large mineral companies can absorb cost volatility across multiple end markets. Smaller processors may have stronger pharmaceutical margins but greater exposure to one mine, one region, or a small number of distributors.

Revenue growth is more likely to come from grade migration than from large volume expansion. Suppliers can increase value by offering low-endotoxin material, controlled particle size, low-heavy-metal grades, pre-dispersed products, and documentation packages tailored to regulated pharmaceutical customers.

What FDA and pharmacopoeial rules apply to bentonite?

Bentonite is regulated as an excipient when used in a drug product, not as an independently approved active pharmaceutical ingredient. The finished product manufacturer is responsible for demonstrating that the material is suitable for its intended use.

The United States Pharmacopeia-National Formulary includes a Bentonite monograph that establishes identity and quality expectations for material meeting the compendial standard.[1] A manufacturer may also use a noncompendial grade if it can establish appropriate specifications and control the material under the applicable drug-quality system.

Relevant controls include:

• Identity and mineral composition.
• Swelling or gel-forming performance.
• Particle-size distribution.
• Loss on drying.
• pH and acid-base behavior.
• Microbial quality.
• Elemental impurities.
• Residual processing contaminants.
• Batch-to-batch uniformity.
• Supplier qualification and change control.

FDA’s Inactive Ingredient Database can support precedent analysis for excipient use, but inclusion does not constitute blanket approval for every route, dosage form, concentration, or product design.[2] Formulators must evaluate route-specific exposure, concentration, patient population, and compatibility with the active ingredient.

European applicants generally rely on applicable European Pharmacopoeia standards, pharmaceutical-quality documentation, and the excipient controls required under the marketing-authorization framework. The International Council for Harmonisation guideline on elemental impurities is particularly relevant because clay minerals can contain naturally occurring metals.[3]

What patents protect bentonite-containing formulations?

Bentonite itself is a naturally occurring mineral and is generally not protected by a basic composition-of-matter patent. Patent protection may arise from a specific formulation, treatment process, combination, or manufacturing method.

Potentially protectable subject matter includes:

• A bentonite grade with defined mineral composition.
• A purified or surface-modified clay.
• A prehydrated or pre-dispersed excipient system.
• A drug formulation combining bentonite with a particular active ingredient.
• A controlled-release matrix containing bentonite.
• A topical or gastrointestinal product with defined rheological properties.
• A method for reducing heavy metals or microbial contamination.
• A process for improving swelling, dispersion, or adsorption.
• A dosage regimen or method of use involving a bentonite-containing product.

These rights are product-specific. They do not create a general monopoly over pharmaceutical bentonite.

There is no standard Orange Book listing for bentonite as an excipient. Paragraph IV litigation would typically concern a finished generic drug containing a bentonite formulation, not the mineral as a standalone material. Patent risk must therefore be reviewed at the finished-product level, including formulation, method-of-use, and manufacturing patents.

When does bentonite lose exclusivity?

Bentonite has no conventional drug exclusivity period. It is a commodity-derived excipient, and market entry is generally open to suppliers that can meet quality, regulatory, and customer-qualification requirements.

The practical barriers are:

• Qualified mineral deposits.
• Consistent composition.
• Validated processing.
• Customer-specific specifications.
• Regulatory documentation.
• Manufacturing change control.
• Long-term supply history.
• Formulation compatibility.
• Contamination control.

A new supplier may need to complete customer audits, comparative testing, stability work, and a change-control process before replacing an incumbent. These barriers can protect supplier relationships even without patent protection.

What generic entry risks exist for bentonite-containing medicines?

Generic entry risk is usually high when bentonite is a conventional excipient and the finished product has no enforceable formulation or method-of-use patents. The generic manufacturer can often source equivalent bentonite from multiple suppliers or use a different suspending agent if the regulatory pathway permits.

Risk is lower when the reference product depends on:

• A narrow viscosity or particle-size profile.
• A proprietary pre-dispersion process.
• A complex adsorption mechanism.
• A controlled-release system.
• A difficult-to-reproduce suspension.
• A product-specific patent covering excipient ratios or manufacturing steps.

For most conventional oral and topical products, the commercial defense is manufacturing know-how, customer loyalty, regulatory history, and brand distribution rather than excipient exclusivity.

How does bentonite compare with alternative pharmaceutical excipients?

Excipient	Main advantage over bentonite	Main disadvantage
Magnesium aluminum silicate	Strong suspension and rheology control	Higher specification complexity
Colloidal silicon dioxide	Effective adsorption and flow aid at low use levels	Different dispersion and mouthfeel profile
Xanthan gum	Strong suspension in aqueous systems	Microbial and processing considerations
Sodium carboxymethylcellulose	Predictable thickening	May require higher use levels
Carbomer	High viscosity at low concentration	pH sensitivity and processing requirements
Synthetic polymers	Consistency and tunability	Higher cost and regulatory documentation
Kaolin	Adsorption and bulk functionality	Less swelling and different mineral profile

Bentonite retains an advantage where low material cost, mineral functionality, and established formulation history matter. It loses ground when formulators prioritize narrow rheological control, appearance, low variability, or simplified global registration.

What geographic factors affect bentonite excipient supply?

Geographic coverage depends on deposit location, processing infrastructure, port access, and regulatory acceptance. The principal supply risk is not a worldwide shortage of bentonite. It is the shortage of a particular validated pharmaceutical grade from an approved source.

Regional supply considerations include:

• North America: established industrial mineral infrastructure and significant pharmaceutical manufacturing demand.
• Europe: strict documentation, environmental controls, and dependence on qualified imported mineral inputs in some markets.
• India: substantial mineral-processing capacity and competitive export potential.
• China: large mineral and chemical supply base, with qualification and documentation varying by supplier.
• Latin America and other mining regions: resource potential but uneven pharmaceutical-processing infrastructure.

Dual sourcing can reduce disruption risk, but changing the mineral source may require comparative quality studies and regulatory assessment because natural clays are compositionally variable.

Key Takeaways

• Bentonite is a niche, recurring pharmaceutical excipient market embedded within the broader specialty-minerals industry.
• Pharmaceutical-grade revenue is driven by purification, testing, documentation, and packaging rather than mining volume alone.
• Public companies generally do not report pharmaceutical bentonite as a standalone financial segment.
• Demand is stable, with growth linked to generic medicines, oral suspensions, topical products, veterinary formulations, and nutraceuticals.
• The main risks are elemental impurities, microbial contamination, mineral variability, freight costs, and substitution.
• Bentonite has no conventional drug exclusivity period and no standalone Orange Book patent estate.
• Patent risk arises from specific finished formulations, treatment processes, delivery systems, and methods of use.
• Supplier differentiation depends on validated quality, traceability, regional inventory, and regulatory support.
• The financial outlook is steady but price-sensitive, with better margins for tested pharmaceutical grades than for industrial bentonite.
• Generic entry risk is high for conventional products unless the finished formulation has meaningful patent or process protection.

Frequently Asked Questions

Is bentonite an FDA-approved pharmaceutical ingredient?

Bentonite is used as an inactive ingredient in drug products when the finished product manufacturer establishes appropriate quality and suitability. FDA approval applies to the finished drug product, not to bentonite as a universally approved standalone substance.[2]

Is pharmaceutical-grade bentonite the same as cosmetic or drilling-grade bentonite?

No. Pharmaceutical-grade material requires tighter specifications, documented testing, traceability, and controls for elemental impurities and microbial quality. Industrial and cosmetic grades cannot be assumed to meet pharmaceutical requirements.

Can bentonite be replaced without changing a drug application?

Not automatically. A supplier or grade change can affect viscosity, sedimentation, dissolution, adsorption, stability, and bioavailability. The regulatory impact depends on the product, dosage form, specifications, and change-control requirements.

Does bentonite create heavy-metal risk in medicines?

It can. Natural clays may contain trace levels of lead, arsenic, mercury, cadmium, and other elements. Pharmaceutical suppliers must test and control elemental impurities under applicable specifications and risk-management requirements.[3]

Are there biosimilar or Paragraph IV risks for bentonite?

Biosimilar risk does not apply to bentonite because it is not a biologic. Paragraph IV risk applies only when a generic applicant challenges a listed patent for a finished drug product containing bentonite or a related formulation.

References

1. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Bentonite monograph. USP-NF.

2. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveingredientdatabase

3. International Council for Harmonisation. (2014). ICH Q3D(R2): Guideline for elemental impurities. https://www.ich.org/page/quality-guidelines

4. Imerys. (2024). Universal registration document and annual financial report. Imerys.

5. Ashapura Minechem Limited. (2024). Annual report. Ashapura Minechem Limited.